Cav1.2 Protein (L-type Calcium Channel Alpha-1C)
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cav1.2 Protein (L-type Calcium Channel Alpha-1C)</th>
</tr>
<tr>
<td class="label">Subunit</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">α1C</td>
<td>CACNA1C</td>
</tr>
<tr>
<td class="label">β1-4</td>
<td>CACNB1-4</td>
</tr>
<tr>
<td class="label">α2δ1-4</td>
<td>CACNA2D1-4</td>
</tr>
<tr>
<td class="label">γ1-8</td>
<td>CACNG1-8</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Amlodipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Verapamil</td>
<td>Phenylalkylamine</td>
</tr>
<tr>
<td class="label">Diltiazem</td>
<td>Benzothiazepine</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">CACNA1C expression</td>
<td>Brain tissue</td>
</tr>
<tr>
<td class="label">L-type calcium current</td>
<td>Neuronal models</td>
</tr>
<tr>
<td class="label">CaMKII activation</td>
<td>Brain tissue</td>
</tr>
<tr>
<td class="label">Nuclear calcium</td>
<td>Cellular models</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">104 edges</a></td>
</tr>
</table>
Cav1.2 (L-type voltage-gated calcium channel alpha-1C subunit, encoded by CACNA1C) is one of the most important calcium channels in [neurons](/entities/neurons), playing critical roles in calcium-dependent signaling, gene expression regulation, synaptic plasticity, and neuronal survival. Dysregulation of Cav1.2 channels contributes to calcium dysregulation - a central hallmark of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease.
Overview
The Cav1.2 channel is a voltage-gated calcium channel (VGCC) that conducts L-type calcium currents - a sustained, slowly inactivating calcium influx in response to membrane depolarization. In neurons, Cav1.2 channels are located throughout the somatodendritic compartment and contribute to[@ltype2014]:
- Calcium-dependent gene transcription
- Synaptic plasticity and [LTP](/mechanisms/long-term-potentiation)
- Dendritic spike generation
- Neurotransmitter release
- Neuronal survival signaling
- Regulation of neuronal excitability
Cav1.2 channels are unique among VGCCs for their sensitivity to dihydropyridines (e.g., nifedipine, amlodipine) and their role in coupling electrical activity to nuclear calcium signaling[@calcium1998].
The channel's alpha-1C subunit (CACNA1C) is one of the most studied genes in neuropsychiatry, with strong associations to bipolar disorder, schizophrenia, and major depression, underscoring its importance in brain function[@cacnac2013].
Structure
Channel Architecture
Cav1.2 is a heteromultimeric channel complex:
Mermaid diagram (expand to render)
Alpha-1C Subunit
The α1C subunit contains:
- Four homologous domains (I-IV), each with 6 transmembrane segments (S1-S6)
- Voltage sensor (S4 segment with positively charged residues)
- Pore region (S5-S6 loop with selectivity filter)
- DHP binding site (in the IVS5-IVS6 region)
- C-terminal tail (contains CaM binding sites, PDZ interactions)
Regulatory Domains
Key regulatory sites on α1C:
- CaM binding domains (CBD): IQ motif in C-terminus
- Phosphorylation sites: Multiple serine/threonine residues
- Protein interaction domains: Proline-rich regions, PDZ-binding motif
Splice Variants
Multiple CACNA1C splice variants generate channel isoforms with:
- Different gating properties
- Altered subcellular localization
- Tissue-specific expression
- Disease-associated variants
Normal Function
Calcium Influx Mechanisms
Cav1.2 channels open in response to membrane depolarization:
Mermaid diagram (expand to render)
Neuronal Functions
In neurons, Cav1.2 channels mediate [@role2005][@molecular2008]:
Synaptic Plasticity
- Required for LTP induction
- Regulates AMPA receptor trafficking
- Controls spine morphology
Gene Expression
- Couples neuronal activity to transcription
- Activates CREB-mediated gene expression
- Regulates BDNF expression
Dendritic Integration
- Generates dendritic calcium spikes
- Amplifies synaptic inputs
- Controls firing patterns
Neurosecretion
- Regulates neurotransmitter release
- Controls hormone secretion (in endocrine neurons)
- Modulates neuropeptide release
Calcium Signaling Cascades
Downstream of Cav1.2 activation:
- Calmodulin activation: Calcium-bound CaM activates multiple enzymes
- CaMKII activation: Ca2+/CaM-dependent protein kinase II
- Calcineurin activation: Calcium-dependent phosphatase
- PKC activation: Protein kinase C
- Gene transcription: Via CREB, NFAT, MEF2
Role in Neurodegenerative Diseases
Alzheimer's Disease
Cav1.2 dysfunction in AD includes [@ltype2020][@ltype2019]:
Calcium dysregulation hypothesis: Cav1.2 contributes to AD through:
- Enhanced channel activity leading to calcium overload
- Increased neuronal vulnerability to Aβ toxicity
- Dysregulated calcium-dependent gene expression
- Altered synaptic plasticity
Aβ interactions: [Amyloid-beta](/proteins/amyloid-beta):
- Directly interacts with voltage-gated calcium channels
- Increases channel open probability
- Promotes calcium dysregulation
- Enhances excitotoxic vulnerability
Therapeutic implications:
- L-type calcium channel blockers (CCBs) being studied for AD
- Nimodipine trials in AD patients
- CCBs may reduce calcium-mediated toxicity
Parkinson's Disease
In PD, Cav1.2 channels contribute to dopaminergic neuron vulnerability [@rejuvenation2007][@calcium2017]:
Pacemaking and calcium overload:
- Substantia nigra dopaminergic neurons have unique pacemaking activity
- Cav1.2 (particularly Cav1.3) contributes to L-type currents
- Continuous calcium influx during pacemaking creates metabolic stress
- Calcium dysregulation contributes to mitochondrial dysfunction
[α-Synuclein](/proteins/alpha-synuclein) interactions:
- α-Synuclein may modulate calcium channel function
- Channel dysfunction enhances α-synuclein toxicity
- Calcium dysregulation promotes α-synuclein aggregation
Neuroprotection strategies:
- Calcium channel blockers (isradipine) being investigated
- Reduces dopaminergic neuron vulnerability
Amyotrophic Lateral SALS
In ALS, Cav1.2 channels [@als2002]:
Motor neuron vulnerability:
- Enhanced calcium influx contributes to excitotoxicity
- Dysregulated calcium homeostasis in motor neurons
- Interaction with ALS-associated proteins (SOD1, FUS, TDP-43)
Therapeutic potential:
- Calcium channel modulators may protect motor neurons
- Combined with riluzole for potential synergistic effects
Huntington's Disease
In HD, Cav1.2 channels [@calcium2018]:
Dysregulated calcium signaling:
- Mutant [huntingtin](/proteins/huntingtin) affects calcium channel function
- Enhanced channel activity contributes to excitotoxicity
- Altered gene expression patterns
Channel dysfunction:
- Dysregulated calcium influx
- Impaired synaptic plasticity
- Enhanced vulnerability to calcium-dependent cell death
Therapeutic Targeting
Calcium Channel Blockers
Clinical Trials
Several clinical trials are investigating CCBs:
- PD: Isradipine phase III trials for neuroprotection
- AD: Nimodipine cognitive function studies
- ALS: CCB combination therapies
Challenges
Key challenges in targeting Cav1.2:
- Peripheral effects: Cardiovascular toxicity limits dosing
- [Blood-brain barrier](/entities/blood-brain-barrier): Variable CNS penetration
- Channel redundancy: Multiple calcium channel types
- Therapeutic window: Balancing efficacy and safety
Biomarkers
Clinical Correlations
Cav1.2 biomarkers may indicate:
- Disease progression
- Treatment response to CCBs
- Calcium dysregulation severity
Cross-Pathway Interactions
Cav1.2 intersects with multiple neurodegenerative pathways [@dysregulation2018]:
Mermaid diagram (expand to render)
- Excitotoxicity: Cav1.2 cooperates with NMDA receptors
- Mitochondrial calcium: Contributes to mitochondrial dysfunction
- Calpain activation: Calcium-dependent protease activation
- Gene transcription: Dysregulated expression patterns
Background
The study of Cav1.2 Protein (L Type Calcium Channel Alpha 1C) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- Calcium Dysregulation in Neurodegeneration
- [Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
- L-type Calcium Channel Alpha-1D (Cav1.3) - CACNA1D
- NMDA Receptor Signaling
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [UniProt Q13936 - CACNA1C](https://www.uniprot.org/uniprot/Q13936)
- [CACNA1C Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/775)
- [L-type Calcium Channels - IUPHAR](https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2289)
References
[- Berridge MJ, "Calcium hypothesis of Alzheimer's disease." Nature Reviews Neuroscience (2020)](https://pubmed.ncbi.nlm.nih.gov/32901135/)
[- Surmeier DJ, "Calcium, ageing, and neuronal vulnerability in Parkinson's disease." Nature Reviews Neuroscience (2019)](https://pubmed.ncbi.nlm.nih.gov/28951921/)
[- Striessnig J, Pinggera A, Kaur G, et al, "L-type calcium channels in brain function." Journal of Neurochemistry (2014)](https://pubmed.ncbi.nlm.nih.gov/25252150/)
[- Dolmetsch RE, Xu K, Lewis RS, "Calcium oscillations increase the efficiency and specificity of gene expression." Nature (1998)](https://pubmed.ncbi.nlm.nih.gov/9582075/)
[- Bialer M, Johannessen SI, Levy RH, et al, "CACNA1C and neuropsychiatric disorders." Epilepsia (2013)](https://pubmed.ncbi.nlm.nih.gov/23551225/)
[- Moosmang S, Haider N, Klugbauer N, et al, "Role of L-type Cav1.2 channels in neuronal function." Cellular and Molecular Life Sciences (2005)](https://pubmed.ncbi.nlm.nih.gov/15928695/)
[- Tippens AL, Lee A, "Molecular regulation of neuronal L-type calcium channel function." Current Opinion in Neurobiology (2008)](https://pubmed.ncbi.nlm.nih.gov/18672175/)
[- O'Donnell F, Smigielski MS, Colomar A, et al, "L-type calcium channels and Alzheimer's disease." Neurobiology of Aging (2020)](https://pubmed.ncbi.nlm.nih.gov/31760112/)
[- Wang Y, Mattson MP, "L-type Ca2+ channel signaling in brain." Brain Research (2019)](https://pubmed.ncbi.nlm.nih.gov/30978367/)
[- Chan CS, Guzman JN, Ilijic E, et al, "'Rejuvenation' protects neurons in mouse models of Parkinson's disease." Nature (2007)](https://pubmed.ncbi.nlm.nih.gov/17558391/)
[- Surmeier DJ, Schumacker PT, Guzman JD, et al, "Calcium, mitochondria, and the pathogenesis of PD." Nature Reviews Neurology (2017)](https://pubmed.ncbi.nlm.nih.gov/28257178/)
[- Van Den Bosch L, Van Damme P, Vandesande W, et al, "ALS and calcium." Neuromuscular Disorders (2002)](https://pubmed.ncbi.nlm.nih.gov/11801361/)
[- TWu J, Fan H, Zhang J, et al, "Calcium dysregulation in Huntington's disease." Journal of Huntington's Disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30188497/)
[- Popugaeva E, Pchitskaya E, Bezprozvanny I, "Dysregulation of neuronal calcium signaling in Alzheimer's disease." Cell Calcium (2018)](https://pubmed.ncbi.nlm.nih.gov/28711874/)